<DOC>
	<DOCNO>NCT02019589</DOCNO>
	<brief_summary>This study Phase 3 , randomize , three-cycle , double-blind , placebo-controlled , parallel group , multiple-dose design . The study design four phase : Screening Period ; Open-Label Estrogen-Priming Period ( Run-In Period ) ; Blinded Treatment Period ; Follow-Up . The Open Label Priming Period Blinded Treatment Period cover total three 28-day cycle . Clinical evaluation perform follow time point : Screening Period : • Screening Period ( approximately 42 Days ) Open-Label Estrogen Priming Period ( Run In Period ) : - Visit 1 Baseline ( Cycle 1 , Day 1 ) - Telephone Interview ( Cycle 1 , Day 28 [ - 3 ±1d ] ) Blinded Treatment Period : - Visit 2 Randomization ( Cycle 2 , Day 12 [ ±2d ] ) - Visit 3 Interim ( Cycle 3 , Day 12 [ ±2d ] ) - Visit 4 End treatment ( Cycle 3 , Day 24 [ ±1d ] ) Follow-Up Period : - Visit 5 Follow-Up ( Approximately 10 day last treatment ) - Telephone Interview ( Approximately 2-4 week completion progestin course ) ( Only apply subject receive approve progestin therapy proliferative endometrium , determine biopsy . )</brief_summary>
	<brief_title>A Phase 3 , Randomized , Three-Cycle , Double-Blind , Placebo-Controlled Study Evaluate Induction Secretory Conversion Endometrium Withdrawal Bleeding Secondary Amenorrhea</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Amenorrhea</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Be female , premenopausal , 18 40 year age ( inclusive , time randomization ) Have secondary amenorrhea , define absence menstruation least 90 day prior Visit 1 ( Cycle 1 , Day 1 ) . Have intact uterus . Be otherwise healthy , judged Investigator physician , base medical evaluation perform screening period prior initial dose Estrace® . The medical evaluation must include : normal nonclinically significant physical examination , include vital sign ( sit blood pressure , heart rate , respiratory rate temperature ) . Acceptable sit systolic blood pressure &lt; 140 mmHg diastolic blood pressure &lt; 90 mmHg screening . A subject may take two antihypertensive medication . normal nonclinically significant pelvic examination perform screen . normal nonclinically significant clinical breast examination perform screen . An acceptable breast examination define mass , adenopathy , finding identify suspicious malignancy . normal nonclinically significant 12lead ECG determine Principal Investigator ( PI ) medical SubInvestigator . Have negative serum pregnancy test Screening , willing use acceptable form nonhormonal birth control ( e.g. , barrier method spermicide ) study . ( The `` rhythm method , '' withdrawal , IUD NOT acceptable method . ) Exclusionary : Be postmenopausal . Be diagnose primary amenorrhea . Have bilateral oophorectomy and/or hysterectomy . Have history thrombosis deep vein artery thromboembolic disorder . Have history coronary artery cerebrovascular disease ( e.g. , myocardial infarction , stroke , TIA ) . Have history liver kidney dysfunction/disorder ( e.g. , hepatitis C chronic renal failure ) . Have history gallbladder dysfunction/disorders ( e.g. , cholangitis , cholecystitis ) , unless gallbladder remove . Have history diabetes , thyroid disease endocrine disease . ( Subjects dietcontrolled diabetes control hypothyroid disease screen exclude . ) Have history undiagnosed vaginal bleeding . Have history endometrial hyperplasia , uterine/endometrial , breast ovarian cancer . Have history malignancy within last 5 year , exception basal cell ( exclude within one year ) squamous cell ( exclude within one year ) carcinoma skin . Have history cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychological , musculoskeletal disease disorder clinically significant opinion Principal Investigator medical SubInvestigator . Have use injectable implantable estrogen , progestin/progesterone , testosterone androgen within last 6 month prior Visit 1 plan use study . Have use follow hormonal product within last 90 day prior Visit 1 plan use study : Vaginal nonsystemic hormonal product ( ring , cream , gel ) vaginal systemic hormonal product ( e.g. , FemRing ) . Transdermal estrogen alone combination estrogen progestin/progesterone product . Oral hormonal birth control oral estrogen and/or progestin/progesterone therapy . Percutaneous estrogen lotions/gels . Have use oral , topical , vaginal , patch testosterone androgen therapy within last 8 week ( 56 day ) prior Visit 1 plan use study . Have use injectable corticosteroid within last 42 day prior Visit 1 plan use study . Have use IUD ( either hormonal nonhormonal ) within previous 90 day prior Visit 1 plan use one study . Have use , within 28 day prior initial dose Estrace® Baseline Visit 1 , plan use study , prescription overthecounter ( OTC ) medication ( include herbal product , St. John 's Wort ) would expect alter progesterone activity . ( For additional detail , see Concomitant Prohibited Medications , Section 4.3 . Have participate another clinical trial within 30 day prior screen , receive investigational drug within 90 day prior initial dose Estrace® , likely participate clinical trial receive another investigational medication study . Have contraindication plan study assessment ( e.g. , endometrial biopsy ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Secondary Amenorrhea</keyword>
	<keyword>SPRY Trial</keyword>
</DOC>